Bristol-Myers Squibb Co
BMYHealthcare|Drug Manufacturers - General|USA
$58.23
-1.10 (-1.85%)
DCF (FCF)
$68.81
Earnings Power
$30.07
Upcoming Data Readouts (43)
Oct 2026
Est. completion
P1P2Multiple Myeloma
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
NCT05372354n=260
Nov 2026
Est. completion
Early P1Multiple Myeloma
A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
NCT05560399n=7
Nov 2026
Est. completion
P1Malignant Pleural Mesothelioma
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
NCT04162015n=22
Nov 2026
Est. completion
Obstructive Hypertrophic Cardiomyopathy
A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT06146660n=600
Dec 2026
Est. completion
Dec 2026
Est. completion
P2Squamous Cell Carcinoma of the Skin
Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin
NCT04204837n=61
Dec 2026
Est. completion
Dec 2026
Est. completion
Metastatic Renal Cell Carcinoma
Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma
NCT04919122n=468
Dec 2026
Est. completion
P2Uterine Cervical Neoplasms
Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer
NCT05492123n=112
Jan 2027
Est. completion
P1P2Sarcoma
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
NCT03465592n=39
Feb 2027
Est. completion
P1Acute Myeloid Leukemia
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT06419634n=105
Feb 2027
Est. completion
P1P2Atypical Teratoid Rhabdoid Tumor
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
NCT05407441n=49
Mar 2027
Est. completion
P2Graft Versus Host Disease
Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant
NCT03924401n=30
Mar 2027
Est. completion
P1Gastric Cancer
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
NCT03044613n=32
Mar 2027
Est. completion
Muscle-invasive Urothelial Carcinoma
A Study to Evaluate Nivolumab in Japanese Participants With Muscle-invasive Urothelial Carcinoma
NCT05779592n=400
Apr 2027
Est. completion
Jun 2027
Est. completion
P1Schizophrenia
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
NCT07061288n=48
Jun 2027
Est. completion
P2Multiple Myeloma
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06297226n=230
Jul 2027
Est. completion
Psoriasis
Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy
NCT07256015n=200
Jul 2027
Est. completion
P2Anemia
A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia
NCT05664737n=189
Awaiting Results (36)
Trials past primary completion date but still active — data readout may be imminent.
Oct 2026
P2
Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
NCT03607890Jul 2026
P1P2
SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
NCT04599140Jul 2026
P3
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
NCT04036435Jul 2026
P3
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
NCT05552976Jul 2026
P4
A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT06112743Jul 2026
P1P2
Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
NCT02393794May 2026
P2
Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas
NCT02451982May 2026
P1P2
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
NCT04396821Apr 2026
P1P2
REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
NCT03610711Mar 2026
P3
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
NCT06140836